Abstract

Spiradenoma and cylindroma are distinctive skin adnexal tumors with sweat gland differentiation and potential for malignant transformation and aggressive behaviour. We present the genomic analysis of 75 samples from 57 representative patients including 15 cylindromas, 17 spiradenomas, 2 cylindroma–spiradenoma hybrid tumors, and 24 low- and high-grade spiradenocarcinoma cases, together with morphologically benign precursor regions of these cancers. We reveal somatic or germline alterations of the CYLD gene in 15/15 cylindromas and 5/17 spiradenomas, yet only 2/24 spiradenocarcinomas. Notably, we find a recurrent missense mutation in the kinase domain of the ALPK1 gene in spiradenomas and spiradenocarcinomas, which is mutually exclusive from mutation of CYLD and can activate the NF-κB pathway in reporter assays. In addition, we show that high-grade spiradenocarcinomas carry loss-of-function TP53 mutations, while cylindromas may have disruptive mutations in DNMT3A. Thus, we reveal the genomic landscape of adnexal tumors and therapeutic targets.

Spiradenoma and cylindroma are skin adnexal tumors that can behave aggressively and undergo malignant transformation. Here, the authors genetically assess a cohort of these adnexal tumours, highlighting recurrent ALPK1 mutations and revealing the genomic landscape of these rare tumours.

Details

Title
ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma
Author
Rashid Mamunur 1 ; van der Horst Michiel 2 ; Mentzel, Thomas 3 ; Butera, Francesca 4 ; Ferreira, Ingrid 1 ; Pance Alena 1   VIAFID ORCID Logo  ; Rütten Arno 3 ; Luzar Bostjan 5 ; Marusic Zlatko 6 ; de Saint Aubain Nicolas 7 ; Ko, Jennifer S 8 ; Billings, Steven D 8 ; Chen, Sofia 1 ; Abi Daoud Marie 9 ; Hewinson, James 1 ; Louzada, Sandra 1 ; Harms, Paul W 10 ; Cerretelli Guia 11 ; Robles-Espinoza, Carla Daniela 12 ; Patel, Rajiv M 10 ; van der Weyden Louise 1 ; Bakal, Chris 4   VIAFID ORCID Logo  ; Hornick, Jason L 13 ; Arends, Mark J 11   VIAFID ORCID Logo  ; Brenn, Thomas 14 ; Adams, David J 1 

 Wellcome Trust Sanger Institute, Experimental Cancer Genetics, Cambridge, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382) 
 Maasstad Hospital, Department of Pathology, Rotterdam, The Netherlands (GRID:grid.416213.3) (ISNI:0000 0004 0460 0556) 
 Dermatopathologie Friedrichshafen, Friedrichshafen, Germany (GRID:grid.500037.1) 
 Division of Cancer Biology. Institute of Cancer Research, Dynamical Cell Systems Laboratory. Chester Beatty Laboratories, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623) 
 Medical Faculty University of Ljubljana, Institute of Pathology, Ljubljana, Slovenia (GRID:grid.8954.0) (ISNI:0000 0001 0721 6013) 
 University Hospital Center Zagreb, Zagreb, Croatia (GRID:grid.412688.1) (ISNI:0000 0004 0397 9648) 
 Institut Jules Bordet, Brussels, Belgium (GRID:grid.418119.4) (ISNI:0000 0001 0684 291X) 
 Cleveland Clinic, Department of Pathology, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725) 
 University of Calgary, Departments of Pathology & Laboratory Medicine and Medicine and The Arnie Charbonneau Cancer Institute, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697) 
10  University of Michigan Medical School, Departments of Pathology and Dermatology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370) 
11  The University of Edinburgh, Institute of Genetics & Molecular Medicine, Division of Pathology, Cancer Research UK Edinburgh Centre, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
12  Wellcome Trust Sanger Institute, Experimental Cancer Genetics, Cambridge, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Universidad Nacional Autónoma de México, Laboratorio Internacional de Investigación sobre el Genoma Humano, Santiago de Querétaro, Mexico (GRID:grid.9486.3) (ISNI:0000 0001 2159 0001) 
13  Harvard Medical School, Department of Pathology, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
14  University of Calgary, Departments of Pathology & Laboratory Medicine and Medicine and The Arnie Charbonneau Cancer Institute, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); The University of Edinburgh, Institute of Genetics & Molecular Medicine, Division of Pathology, Cancer Research UK Edinburgh Centre, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2226767601
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.